做多
已更新

AVEO missed earnings - kidney cancer treatment too thinly traded

81
Medical stock that's too thinly traded got mixed review on clinical trial results on Tivozanib, which showed efficacy, just not to level expected and testing new low for 2018 at 2.03 and below full fibonacci retracement of 2.10 as prior low. NASDAQ:AVEO
注释
快照
Currently at 618fibretracement
注释
Full 241% retracement and bounce to 161%. Sign of bouncing cat?

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。